
CJC-1295 with DAC
Long-acting peptide studied for sustained growth-hormone signalling in research models.
For Research Use Only
Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.
The lower price is applied automatically once your cart holds 5 or more of this vial.
Bacteriostatic water included
About this peptide
CJC-1295 with DAC is a modified version of a natural hormone signal called GHRH, which tells the body to release growth hormone. The DAC attachment helps it remain active in the bloodstream for longer than shorter-acting versions. Researchers study its effects on growth-hormone patterns, recovery, and body-composition markers.
Why researchers reach for CJC-1295 with DAC
Extended half-life
Albumin binding via DAC gives a multi-day plasma profile in research.
Pulsatile GH studies
Used to probe growth-hormone-releasing pathways in vivo.
Pairs with GHRPs
Common comparator alongside Ipamorelin in preclinical protocols.
Key features
- ≥99% HPLC purity
- DAC-conjugated tetrasubstituted GHRH(1-29)
- Mass-spec verified
- Cold-chain dispatch
How it works
GHRH receptor agonism
Binds pituitary GHRH receptors to trigger GH release.
Albumin tethering
Maleimide DAC forms covalent bond with plasma albumin cysteine-34.
Sustained IGF-1 tone
Extends downstream IGF-1 elevation in preclinical models.
Research dosage guidelines
Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.
| Range | Reported dose | Note |
|---|---|---|
| Typical reconstitution | 2 mL bacteriostatic water | Yields 1 mg/mL (1000 mcg/mL) |
| Reported research range | 1–2 mg/week | Reference only |
Tracking this compound? Registered researchers can log active CJC-1295 with DAC protocols in their private Research Log.
Timing in research protocols
Weekly or every-other-week dosing — clock time is not a variable.
- The pivotal human pharmacokinetic study (Teichman et al., JCEM 2006) used weekly or biweekly subcutaneous doses across 28–49 day study periods.
- Reported elimination half-life of roughly 5.8–8.1 days, with IGF-I still elevated up to 28 days after repeated doses.
- Because of that long half-life, time of day and fed or fasted state are pharmacologically immaterial; the spacing between doses is the operative variable.
- Study durations in the published literature run to approximately seven weeks.
Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.
Technical specifications
- Sequence
- Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 (modified GRF 1-29 with DAC)
- Class
- GHRH analogue + DAC
- Molecular weight
- 3367.9 g/mol
- Purity
- ≥99% (HPLC)
- Form
- Lyophilized powder
- Vial size
- 2 mg
- Storage (lyophilised vial)
- Cool, dry and protected from light
- Storage (after reconstitution)
- 2–8°C
Published research
Peer-reviewed literature on CJC-1295 with DAC. Links open in a new tab.
Research use notice
Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.
